News & Research - HBM Partners AG

Important legal information

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

China's Leading Online B2C Pharmacy and Healthcare Services Platform Jianke Raises USD130 Million in Series B Financing (66 KB)
4.9.2018
Download
Forbius (Formation Biologics) Awarded $18.8 Million Grant by the Cancer Prevention and Research Institute of Texas (45 KB)
24.8.2018
Download
Gynesonics Receives FDA Clearance to Market New Treatment for Uterine Fibroids (116 KB)
22.8.2018
Download
Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma (117 KB)
21.8.2018
Download
TPG Invests in Sai Life Sciences (190 KB)
25.7.2018
Download
iTeos Therapeutics Completes $75 Million Series B Financing (266 KB)
20.6.2018
Download
Hookipa and Gilead Enter into a Collaboration and License Agreement (102 KB)
5.6.2018
Download
Sublimity Therapeutics Closes US$64 Million Financing to Fund Development of New Oral Ulcerative Colitis Drug Candidate (155 KB)
22.5.2018
Download
Corvidia Announces Series B Funding Closure (159 KB)
25.4.2018
Download
Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders (142 KB)
18.12.2017
Download

<1 2 345 6 >

Interview with Andreas Wicki (351 KB)
Download Read more
Interview with Ivo Staijen (263 KB)
17.7.2019
Download Read more
Biotech-Unternehmen schwimmen im Geld (309 KB)
25.5.2019
Download Read more
„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)
13.8.18
Download Read more
Die Reize der Swiss Biotechs (581 KB)
25.7.2018
Download Read more
Der Kampf gegen das Vergessen (561 KB)
4.6.2018
Download Read more
Die Zuversicht für den Biotech-Sektor wächst (328 KB)
18.11.2017
Download Read more
Novartis setzt auf Nuklearmedizin (106 KB)
31.10.2017
Download Read more
Novartis's neue Wette im Krebsgeschäft (1502 KB)
31.10.2017
Download Read more
Trends und Chancen für den Anleger (840 KB)
1.9.2017
Download Read more
Strong Vital Signs in Biotech Innovation (4732 KB)
1.9.2017
Download Read more
Fokus auf Innovation (118 KB)
1.9.2017
Download Read more
Wie Anleger erfolgreich in Biotech investieren (535 KB)
27.5.2017
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

Credits

Sitemap

Important legal information

China's Leading Online B2C Pharmacy and Healthcare Services Platform Jianke Raises USD130 Million in Series B Financing (66 KB)

Forbius (Formation Biologics) Awarded $18.8 Million Grant by the Cancer Prevention and Research Institute of Texas (45 KB)

Gynesonics Receives FDA Clearance to Market New Treatment for Uterine Fibroids (116 KB)

Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma (117 KB)

TPG Invests in Sai Life Sciences (190 KB)

iTeos Therapeutics Completes $75 Million Series B Financing (266 KB)

Hookipa and Gilead Enter into a Collaboration and License Agreement (102 KB)

Sublimity Therapeutics Closes US$64 Million Financing to Fund Development of New Oral Ulcerative Colitis Drug Candidate (155 KB)

Corvidia Announces Series B Funding Closure (159 KB)

Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders (142 KB)

Interview with Andreas Wicki (351 KB)

Interview with Ivo Staijen (263 KB)

Biotech-Unternehmen schwimmen im Geld (309 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)

Die Reize der Swiss Biotechs (581 KB)

Der Kampf gegen das Vergessen (561 KB)

Die Zuversicht für den Biotech-Sektor wächst (328 KB)

Novartis setzt auf Nuklearmedizin (106 KB)

Novartis's neue Wette im Krebsgeschäft (1502 KB)

Trends und Chancen für den Anleger (840 KB)

Strong Vital Signs in Biotech Innovation (4732 KB)

Fokus auf Innovation (118 KB)

Wie Anleger erfolgreich in Biotech investieren (535 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

Biopharma M&A Update H1 2019 and Potential Implications of Mega Mergers for Smaller Biopharma Deal Making (492 KB)

HBM Pharma / Biotech M&A Report 2018 (1263 KB)

Pharma / Biotech M&A Transactions 2005-2018 (106 KB)